Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
29
pubmed:dateCreated
2003-7-14
pubmed:abstractText
The effects of estrogen and anti-estrogen are mediated through the estrogen receptors (ER) alpha and beta, which function as ligand-induced transcriptional factors. Recently, one of the phthalate esters, n-butylbenzyl phthalate (BBP), has been shown to induce estrogen receptor-mediated responses. By using the truncated types of ER mutants, we revealed that activation function-1 (AF-1) activity was necessary for the BBP-dependent transactivation function of ERalpha. AF-1 is also known to be responsible for the partial agonistic activity of tamoxifen. Whereas tamoxifen exhibits an anti-estrogenic effect on proliferation of the MCF-7 breast cancer cell line, BBP showed an estrogenic effect on MCF-7 to stimulate proliferation. In vivo and in vitro binding assays revealed that whereas 4-hydroxytamoxifen (OHT) induced binding of ERalpha to both an AF-1 coactivator complex (p68/p72 and p300) and corepressor complexes (N-CoR/SMRT), BBP selectively enhanced the binding to the AF-1 coactivators. We also showed that the transcriptional activity of OHT-bound ERalpha was modulated by the ratio between the AF-1 coactivator and corepressor complexes. Expression of a dominant-negative type of N-CoR inhibited the interaction between OHT-bound ERalpha and N-CoR/SMRT and enhanced the transcriptional activity of OHT-bound ERalpha. Furthermore, the cell growth of MCF-7 stably expressing the dominant-negative type of N-CoR was enhanced by the addition of OHT. These results indicated that fully activated AF-1 induces the stimulation of breast cancer growth and that the ratio between AF-1 coactivators and corepressors plays a key role to prevent proliferation of tumor by tamoxifen.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0021-9258
pubmed:author
pubmed:issnType
Print
pubmed:day
18
pubmed:volume
278
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
26704-14
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:12738788-3T3 Cells, pubmed-meshheading:12738788-Animals, pubmed-meshheading:12738788-Binding, Competitive, pubmed-meshheading:12738788-Breast Neoplasms, pubmed-meshheading:12738788-Cell Division, pubmed-meshheading:12738788-Estrogen Receptor alpha, pubmed-meshheading:12738788-Female, pubmed-meshheading:12738788-Humans, pubmed-meshheading:12738788-Mice, pubmed-meshheading:12738788-Neoplasms, Hormone-Dependent, pubmed-meshheading:12738788-Phthalic Acids, pubmed-meshheading:12738788-Protein Binding, pubmed-meshheading:12738788-Protein Structure, Tertiary, pubmed-meshheading:12738788-Receptors, Estrogen, pubmed-meshheading:12738788-Receptors, Interferon, pubmed-meshheading:12738788-Repressor Proteins, pubmed-meshheading:12738788-Tamoxifen, pubmed-meshheading:12738788-Transcriptional Activation, pubmed-meshheading:12738788-Transfection, pubmed-meshheading:12738788-Tumor Cells, Cultured, pubmed-meshheading:12738788-Two-Hybrid System Techniques
pubmed:year
2003
pubmed:articleTitle
Full activation of estrogen receptor alpha activation function-1 induces proliferation of breast cancer cells.
pubmed:affiliation
Institute of Applied Biochemistry, University of Tsukuba, 1-1-1 Tenno-dai, Tsukuba Science City, Ibaraki 305-8572, Japan.
pubmed:publicationType
Journal Article, In Vitro, Research Support, Non-U.S. Gov't